Catalent (CTLT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.24. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -125%. A quarter ago, it was expected that this maker of drug delivery technologies would post a loss of $0.03 per share when it actually produced a loss of $0.24, delivering a surprise of -700%.Over the last four quarters, the company has ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of registrant as specified in its charter) _____________________________ Delaware 20-8737 ...

• Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3'23 and ~$60 million in Q3'24, increased 11% compared to Q3'23. (1) • Q3'24 Adjusted EBITDA of $163 million increased 55% as reported, or 53% in constant currency, compared to Q3'23. "I am pleased to report that in the fiscal third quarter Catalent returned to growth, including double-digit non-COVID year-on-year revenue growth. We also continued our momentum in both the Biologics segment and the Pharma and Consumer Health segment, w ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight comp ...

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Catalent, Inc. (NYSE:CTLT) by Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation. Under the terms of the agreement, Catalent stockholders will receive $63.50 in cash for each share of Catalent common stock owned. If you own shares of Catalent, Inc. click here. Is the Proposed Acquisiti ...

Guido Mieth By Marshall Gordon, Elisa Mazen and Charine Park Diabetes and Obesity Markets Large and Growing Drugs based on GLP-1 are developing into a mega blockbuster market for the treatment of diabetes and obesity. Danish pharmaceutical maker Novo Nordisk (NVO) has been involved for decades in the treatment of diabetes and is pioneering the advanced pharmaceutical treatment of obesity. ClearBridge initially purchased Novo in 2001, well ahead of the first clinical trials for its type 2 diabetes treatment ...

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: NGM has agreed to be acquired by affiliat ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives. One area of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) 14 Schoolhouse Road Catalent, Inc. Somerset, New Jersey 08873 (Exact name of registrant as specified in its chart ...

Catalent, Inc. (CTLT) reported second-quarter fiscal 2024 adjusted loss per share of 24 cents against the year-over-year period’s earnings per share (EPS) of 67 cents. The metric was wider than the Zacks Consensus Estimate of a loss of 3 cents per share.The adjustments include charges related to amortization, and acquisition, integration and other special items’ costs, among others.The company’s GAAP loss per share was $1.12 during the quarter, against the year-over-year period’s EPS of 44 cents.Revenues in ...